THE ROLE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF PSORIASIS: A POTENTIAL THERAPEUTIC APPROACH

Antoni Majda; Julia Pająk; Kacper Kucharski; Anna Kamosińska; Adam Kowal

doi:10.31435/ijitss.1(49).2026.5073

Authors

Antoni Majda MD, Provincial Specialist Hospital in Wrocław, Poland https://orcid.org/0009-0006-4357-513X
Julia Pająk MD, 4th Military Clinical Hospital with Polyclinic, Independent Care Institution, Wrocław, Poland https://orcid.org/0009-0007-0882-9365
Kacper Kucharski MD, Jan Mikulicz Radecki University Clinical Hospital, Wrocław, Poland https://orcid.org/0009-0004-5709-8974
Anna Kamosińska MD, 4th Military Clinical Hospital with Polyclinic, Independent Care Institution, Wrocław, Poland https://orcid.org/0009-0005-0718-2112
Adam Kowal MD, Jan Mikulicz Radecki University Clinical Hospital, Wrocław, Poland https://orcid.org/0009-0007-7779-598X

DOI:

https://doi.org/10.31435/ijitss.1(49).2026.5073

Keywords:

Psoriasis, GLP-1 Receptor Agonists, PASI Index, Metabolism, Pro-Inflammatory Cytokines

Abstract

Psoriasis is a chronic inflammatory disease with complex pathogenesis. There is growing evidence that excess body fat can lead to systemic inflammation, which exacerbates the symptoms of the disease.

The aim of this study was to review the available scientific literature on the use of GLP-1 receptor agonists in the treatment of psoriasis. Their mechanism of action not only includes better glycaemic control, weight loss and reduction of inflammation, but also has a significant effect on the immune response of T lymphocytes, NK cells and macrophages.

Despite small study groups and a short observation period, the available clinical studies show a reduction in the PASI index and inflammatory markers, with the positive therapeutic effect being most noticeable in patients with obesity and type 2 diabetes.

GLP-1 receptor agonists are a promising therapeutic pathway for the treatment of psoriasis, especially in patients with metabolic disorders. Unfortunately, further long-term clinical trials involving a larger number of subjects are needed to confirm the efficacy and safety of this form of treatment.

References

Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA, 323(19), 1945–1960. https://doi.org/10.1001/jama.2020.4006

Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024). The immunology of psoriasis—Current concepts in pathogenesis. Clinical Reviews in Allergy & Immunology, 66(2), 164–191. https://doi.org/10.1007/s12016-024-08991-7

Xu, X., Lin, L., Chen, P., Yu, Y., Chen, S., Chen, X., & Shao, Z. (2019). Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Research and Clinical Practice, 150, 167–173. https://doi.org/10.1016/j.diabres.2019.03.002

Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., Ashcroft, D. M., & Global Psoriasis Atlas. (2020). National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ, 369, m1590. https://doi.org/10.1136/bmj.m1590

Wełniak, A., Nowicka, A., & Czajkowski, R. (2023). Correlation between the components of the metabolic syndrome and psoriasis. Forum Dermatologicum, 9(2), 56–60. https://doi.org/10.5603/FD.a2023.0007

Dobrowolski, P., Prejbisz, A., Kuryłowicz, A., Baska, A., Burchardt, P., Chlebus, K., Dzida, G., Jankowski, P., Jaroszewicz, J., Jaworski, P., Kamiński, K., Kapłon-Cieślicka, A., Klocek, M., Kukla, M., Mamcarz, A., Mastalerz-Migas, A., Narkiewicz, K., Ostrowska, L., Śliż, D., Tarnowski, W., … Bogdański, P. (2022). Metabolic syndrome—A new definition and management guidelines: A joint position paper by multiple Polish societies. Archives of Medical Science, 18(5), 1133–1156. https://doi.org/10.5114/aoms/152921

Jensen, P., & Skov, L. (2016). Psoriasis and obesity. Dermatology, 232(6), 633–639. https://doi.org/10.1159/000455840

Kong, Y., Zhang, S., Wu, R., Su, X., Peng, D., Zhao, M., & Su, Y. (2019). New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids in Health and Disease, 18(1), 171. https://doi.org/10.1186/s12944-019-1115-3

Gręblowski, P., Łosiowska, A., & Kłoda, K. (2024). The role of GLP-1 analogues, including oral semaglutide, in the treatment of type 2 diabetes—Based on clinical trial results and current guidelines. Lekarz POZ, 10(6).

Krajewski, P. K., Złotowska, A., & Szepietowski, J. C. (2024). The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: A systematic review of anti-inflammatory and metabolic effects. Journal of Clinical Medicine, 13(21), 6292. https://doi.org/10.3390/jcm13216292

Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., Loretelli, C., D'Addio, F., Berra, C., Ben Nasr, M., Zuccotti, G., & Fiorina, P. (2022). The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacological Research, 182, 106320. https://doi.org/10.1016/j.phrs.2022.106320

Biedka, K., Wesołowski, M., Ziobro, O., Błaszczyk, K., Bulski, J., & Sobaś, A., et al. (2025). Semaglutide in modern medicine: Therapeutic opportunities in obesity and the emerging challenge of NAION—A narrative review. Family Medicine & Primary Care Review, 27(2), 215–221. https://doi.org/10.5114/fmpcr.2025.150180

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Hildebrandt, X., Ibrahim, M., & Peltzer, N. (2023). Cell death and inflammation during obesity: “Know my methods, WAT(son)”. Cell Death and Differentiation, 30(2), 279–292. https://doi.org/10.1038/s41418-022-01062-4

Tilg, H., Ianiro, G., Gasbarrini, A., & Adolph, T. E. (2025). Adipokines: Masterminds of metabolic inflammation. Nature Reviews Immunology, 25(4), 250–265. https://doi.org/10.1038/s41577-024-01103-8

Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P. O., Ricordi, C., & Pastori, R. L. (2012). Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplantation, 21(4), 633–648. https://doi.org/10.3727/096368911X576027

Ferdaoussi, M., Abdelli, S., Yang, J. Y., Cornu, M., Niederhauser, G., Favre, D., Widmann, C., Regazzi, R., Thorens, B., Waeber, G., & Abderrahmani, A. (2008). Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis. Diabetes, 57(5), 1205–1215. https://doi.org/10.2337/db07-1214

Drucker, D. J. (2016). The cardiovascular biology of glucagon-like peptide-1. Cell Metabolism, 24(1), 15–30. https://doi.org/10.1016/j.cmet.2016.06.009

Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2016). Exenatide expresses anti-inflammatory properties in cultured human monocytes/macrophages. Pharmacological Reports, 68(2), 329–337. https://doi.org/10.1016/j.pharep.2015.10.008

Lu, C., Xie, T., Guo, X., Wu, D., Li, S., Li, X., Lu, Y., & Wang, X. (2019). Exendin-4 mitigates inflammatory responses in macrophages. International Immunopharmacology, 77, 105969. https://doi.org/10.1016/j.intimp.2019.105969

Shen, X., Luo, L., Yang, M., Lin, Y., Li, J., & Yang, L. (2020). Exendin-4 inhibits oxidative stress in β-cells. International Journal of Molecular Medicine, 45(4), 1237–1249. https://doi.org/10.3892/ijmm.2020.4490

Costache, D. O., Feroiu, O., Ghilencea, A., Georgescu, M., Căruntu, A., Căruntu, C., Țiplica, S. G., Jinga, M., & Costache, R. S. (2022). Skin inflammation modulation via cytokine inhibitors in psoriasis. International Journal of Molecular Sciences, 23(9), 5198. https://doi.org/10.3390/ijms23095198

Buysschaert, M., Baeck, M., Preumont, V., Marot, L., Hendrickx, E., Van Belle, A., & Dumoutier, L. (2014). Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: A prospective case-series study. The British Journal of Dermatology, 171(1), 155–161. https://doi.org/10.1111/bjd.12886

Malavazos, A. E., Meregalli, C., Sorrentino, F., Vignati, A., Dubini, C., Scravaglieri, V., Basilico, S., Boniardi, F., Spagnolo, P., Malagoli, P., Romanelli, P., Secchi, F., & Iacobellis, G. (2023). Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type 2 diabetes. Endocrinology, Diabetes & Metabolism Case Reports, 2023(3), 23-0017. https://doi.org/10.1530/EDM-23-0017

Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O'Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., Kirby, B., O'Connell, J., & O'Shea, D. (2011). Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia, 54(11), 2745–2754. https://doi.org/10.1007/s00125-011-2232-3

Buysschaert, M., Tennstedt, D., & Preumont, V. (2012). Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes & Metabolism, 38(1), 86–88. https://doi.org/10.1016/j.diabet.2011.11.004

Gerdes, S., Rostami-Yazdi, M., & Mrowietz, U. (2011). Adipokines and psoriasis. Experimental Dermatology, 20(2), 81–87. https://doi.org/10.1111/j.1600-0625.2010.01210.x

Jensen, P., Zachariae, C., Christensen, R., Geiker, N. R., Schaadt, B. K., Stender, S., Hansen, P. R., Astrup, A., & Skov, L. (2013). Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatology, 149(7), 795–801. https://doi.org/10.1001/jamadermatol.2013.722

Roongpisuthipong, W., Pongpudpunth, M., Roongpisuthipong, C., & Rajatanavin, N. (2013). The effect of weight loss in obese patients with chronic stable plaque-type psoriasis. Dermatology Research and Practice, 2013, 795932. https://doi.org/10.1155/2013/795932

Castaldo, G., Rastrelli, L., Galdo, G., Molettieri, P., Rotondi Aufiero, F., & Cereda, E. (2020). Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition, 74, 110757. https://doi.org/10.1016/j.nut.2020.110757

Atiquzzaman, N., Razdolsky, N., & Parmar, M. S. (2025). GLP-1 receptor agonists: Emerging therapeutic potential in psoriasis management—Current evidence and future outlook. European Journal of Clinical Pharmacology, 81(11), 1569–1581. https://doi.org/10.1007/s00228-025-03898-4

Masson, W., Lobo, M., & Molinero, G. (2020). Psoriasis and cardiovascular risk: A comprehensive review. Advances in Therapy, 37(5), 2017–2033. https://doi.org/10.1007/s12325-020-01346-6

Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C., Skov, L., Knop, F. K., & Vilsbøll, T. (2015). Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients: A randomized placebo-controlled trial. Journal of the European Academy of Dermatology and Venereology, 29(3), 555–559. https://doi.org/10.1111/jdv.12629

Chang, G., Chen, B., & Zhang, L. (2022). Efficacy of GLP-1 receptor agonist liraglutide in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis. Journal of Dermatological Treatment, 33(3), 1299–1305. https://doi.org/10.1080/09546634.2021.1882658

Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., La Placa, M., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. (2025). Benefit-risk assessment of GLP-1 receptor agonists: Implications for dermatologists and plastic surgeons. Dermatology and Therapy, 15(11), 3173–3193. https://doi.org/10.1007/s13555-025-01537-5

Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Sfondrini, G., Grimalt, M., García, P., Nadal, C., & Masmiquel, L. (2025). Dermatologic and metabolic benefits of semaglutide in psoriasis with obesity: A six-month prospective cohort study. Clinical and Experimental Dermatology. Advance online publication. https://doi.org/10.1093/ced/llaf473

Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes: State-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102

Persson, C., Eaton, A., & Mayrovitz, H. N. (2025). A closer look at the dermatological profile of GLP-1 agonists. Diseases, 13(5), 127. https://doi.org/10.3390/diseases13050127

Patel, S., & Niazi, S. K. (2025). Emerging frontiers in GLP-1 therapeutics: A comprehensive evidence base (2025). Pharmaceutics, 17(8), 1036. https://doi.org/10.3390/pharmaceutics17081036